Andrew Huberman joins Hims & Hers board, bringing science chops to a telehealth growth push

Why this matters now

Andrew Huberman built a massive health audience by turning lab insights into everyday guidance on sleep, training, hormones, supplements, and longevity. His Huberman Lab YouTube channel tops 8 million subscribers, and his health and science podcast regularly ranks among the leaders in its category.

Now he is stepping directly into the business side at Hims & Hers. He will advise the company on scientific rigor and brand strategy and contribute separate promotion via his podcast. Scicomm Media, his media arm, will run paid Hims & Hers ads.

Huberman says the editorial line will hold. "We will never filter information differently because of a brand relationship," he told Business Insider, adding that Hims encouraged him to keep educating independent of "any kind of product or platform."

How the partnership came together

Huberman contacted CEO Andrew Dudum through a mutual connection, and the two spent roughly the past six to eight months talking about where consumer healthcare is headed. "We have some overlapping interests," Huberman said, including bringing the "best healthcare practices to the broadest number of people." As he put it, "Joining the board allows me to do that rather than just only talk about how Hims & Hers can do that."

On a joint call Monday, both described a shared aim to make personalized care easier to access. Dudum asked, "How do you empower the masses around the globe to feel better and take more agency in their life?" Huberman framed Hims as addressing "this enormous gap that's existed in the middle" between time strapped traditional care and pricey concierge models, saying "The middle 95%" should be able to get personalized support.

This is a deeper role than Huberman's earlier advising with fitness and sleep brands. It includes fiduciary duties and hands on strategy, and it puts him on a board that already features leaders such as David Wells, the former Netflix CFO, and Kofi Amoo-Gottfried, DoorDash's former CFO. Both Huberman and Dudum said he remains free to cover the broader category on his show.

Smart investors adapt their tools as new ideas reshape how decisions get made. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.

Peptides, personalization, and Hims' positioning

Beyond hair loss and erectile dysfunction, Hims & Hers has broadened its menu to include peptide therapies, preventive care, testosterone offerings, and weight-loss treatments. That links Huberman to a company that can provide many therapies he talks about, and it comes as Hims leans into optimization topics like testosterone and injectable peptides. Huberman ranks among the most prominent mainstream voices on injectable peptides, while Dudum has been building a business to offer them.

Crucially, Hims' peptide push began before Huberman's board role and prior to a recent HHS move that, for a limited time, allowed certain headline-grabbing peptides to be prescribed. Late in 2024, the company struck a deal tied to a California peptide site and, in February 2025, made the acquisition public.

In recent weeks, Hims previewed Peptides+, a forthcoming part of its website that will let consumers obtain various peptides once regulators give the green light, including BPC-157, plus other widely used wellness options such as NAD+ and vitamin B12. Huberman said he is not looking to spur broad use without a need: "I don't know if somebody without an injury needs BPC and TB-500," he said.

One of the big draws for him was Hims' plan to oversee peptide production end-to-end and to help shape the broader discussion about the capabilities and limits of peptides. "You have to be a channel, not a dam to this kind of information," he said. Dudum echoed that the fast evolving world of personalized health and longevity "needs to be navigated extremely carefully and very cautiously."

Independence, disclosure, and investor takeaways

The Huberman Lab channel will continue to cover upsides, risks, and uncertainty across the category. He did not specify how each episode, post, or short will disclose his board role and separate marketing relationship, though Scicomm Media will run ads for Hims & Hers and receive payment. The company's pitch is a more rigorous path through wellness noise. As Huberman put it, "It really turns people into scientists of themselves."

Competition is building. Telehealth rivals such as Ro and Midi, along with longevity clinics, diagnostics startups, and consumer health brands, are all chasing the same mainstream middle. Hims brings scale with nearly 3 million customers, in house pharmacy and manufacturing, and now a prominent voice tied to its expanding playbook.

Finding small advantages from thoughtful tools can help investors navigate uncertainty with confidence. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.